Patents by Inventor Peter Sennhenn
Peter Sennhenn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240033363Abstract: The present invention relates to small molecule compounds that allosterically inhibit ALC1 (CHD1L) and which induce the trapping of PARP1, PARP2 and/or PARP3 on chromatin or at DNA damage sites. Disruption of the chromatin remodeling forces of ALC1 through these agents enables a highly selective therapy for targeting the DNA damage functions of PARP enzymes in several proliferative diseases, notably BRCA-deficient cancers. Via inhibition of the enzymatic activity, the compounds engage the synthetic lethality between BRCA1/2 and ALC1. By trapping PARP enzymes, inhibitors of ALC1 potentiate the cancer cell killing properties of PARP inhibitors, enable therapeutic approaches where ALC1 is amplified as an oncogene, therapeutically make it possible to overcome PARP inhibitor resistance mechanisms and enable an alternative approach to the treatment of germline or acquired BRCA1/BRCA2 deficiency, including tumors defined by “BRCAness” or other changes in DNA repair networks.Type: ApplicationFiled: December 3, 2021Publication date: February 1, 2024Inventors: William M. Menzer, Gunnar Knobloch, Corinna Lieleg, Adrian Schomburg, Andreas Ladurner, Peter Sennhenn
-
Publication number: 20230348453Abstract: The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder—such as a mixed phenotype acute leukaemia (MPAL)—characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein.Type: ApplicationFiled: April 21, 2021Publication date: November 2, 2023Inventors: Peter SENNHENN, Stefan BISSINGER, Hannes LOFERER, David BANCROFT, Tillmann MICHELS, Nisit KHANDELWAL
-
Publication number: 20230228760Abstract: The invention is based on the identification of the intracellular kinase calcium/calmodulin-dependent protein kinase 1D (CAMK1D) as a key checkpoint inhibitor in tumour cells mediating resistance against cytotoxic T lymphocytes (CTL). CAMK1D was identified in PD-L1 refractory tumours to impair CTL-induced death receptor signalling and apoptosis via caspase inhibition. The invention offers therapeutic approaches involving impairing CAMK1D immune checkpoint function by various CAMK1D inhibitors, especially nucleic acid or small molecule inhibitors of CAMK1D and/or treatments involving CAMK1D inhibitors with death receptor agonists. The medical approaches of the invention are useful for treating subjects suffering from various proliferative disorders; preferably such proliferative disorders that are characterized by a resistance to CTL mediated immune responses, or which are refractory or resistant to treatments with other immune checkpoint therapies, such as PD1-PDL1 antagonistic treatments.Type: ApplicationFiled: May 17, 2021Publication date: July 20, 2023Applicant: iOmx Therapeutics AGInventors: Valentina VOLPIN, Philipp BECKHOVE, Antonio SORRENTINO, Michael BOUTROS, Nisit KHANDELWAL, Tillmann MICHELS, Peter SENNHENN
-
Publication number: 20230192701Abstract: The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder—such as a mixed phenotype acute leukaemia (MPAL)—characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein.Type: ApplicationFiled: April 28, 2021Publication date: June 22, 2023Applicant: iOmx Therapeutics AGInventors: Peter SENNHENN, Hannes LOFERER, David BANCROFT, Art KLUGE
-
Publication number: 20210387982Abstract: The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.Type: ApplicationFiled: October 22, 2019Publication date: December 16, 2021Inventors: Peter SENNHENN, Sebastian MEIER-EWERT, Nisit KHANDELWAL, David BANCROFT
-
Publication number: 20210379067Abstract: The invention relates to a kinase inhibitor, in particular an inhibitor of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitor of the invention displays, eg functional and ADMET properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise the kinase inhibitor, including those formulated for oral administration, such as in unit dose form that comprise particular ranges or amounts of the kinase inhibitor. The kinase inhibitor or pharmaceutical composition may be used in the treatment of a proliferative disorder, such as a leukaemia or solid tumour.Type: ApplicationFiled: October 22, 2019Publication date: December 9, 2021Inventors: Peter SENNHENN, Sebastian MEIER-EWERT, Nisit KHANDELWAL
-
Publication number: 20210179602Abstract: The invention relates to a kinase inhibitor, in particular an inhibitor of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitor of the invention displays, eg functional and ADMET properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise the kinase inhibitor, including those formulated for oral administration, such as in unit dose form that comprise particular ranges or amounts of the kinase inhibitor. The kinase inhibitor or pharmaceutical composition may be used in the treatment of a proliferative disorder, such as a leukaemia or solid tumour.Type: ApplicationFiled: April 23, 2019Publication date: June 17, 2021Applicant: iOmx Therapeutics AGInventors: Peter Sennhenn, Sebastian Meier-Ewert, Nisit Khandelwal
-
Publication number: 20210040486Abstract: The invention is based on the surprising finding that SIK3 is associated with resistance against anti-tumour immune responses. In particular, the invention provides methods for treating proliferative diseases using inhibitors of SIK3, especially nucleic acid or small molecule inhibitors of SIK3. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of certain pro-inflammatory signalling pathways, and/or to kill such cells and/or methods for treating proliferative diseases, using a SIK3 inhibitor together with ligands or agonists of such signalling pathways.Type: ApplicationFiled: April 20, 2018Publication date: February 11, 2021Inventors: Antonio SORRENTINO, Philipp BECKHOVE, Tillmann MICHELS, Nisit KHANDELWAL, Michael BOUTROS, Marco BREINIG, Peter SENNHENN, Sebastian MEIER-EWERT, Valentina VOLPIN, Ayse Nur MENEVSE
-
Patent number: 10647687Abstract: The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.Type: GrantFiled: November 10, 2015Date of Patent: May 12, 2020Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
-
Patent number: 10280179Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterized by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.Type: GrantFiled: September 18, 2017Date of Patent: May 7, 2019Assignee: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
-
Publication number: 20180362475Abstract: The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.Type: ApplicationFiled: November 10, 2015Publication date: December 20, 2018Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
-
Publication number: 20180065982Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.Type: ApplicationFiled: September 18, 2017Publication date: March 8, 2018Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
-
Patent number: 9802956Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.Type: GrantFiled: July 15, 2014Date of Patent: October 31, 2017Assignee: Helmholtz Zentrum Munchen-Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
-
Publication number: 20160222025Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.Type: ApplicationFiled: July 15, 2014Publication date: August 4, 2016Inventors: Marcus CONRAD, Joel SCHICK, Bettina PRONETH, Peter SENNHENN
-
Patent number: 8203001Abstract: The present invention encompasses compounds of general formula (1) wherein R1, M1, L1 and Q are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.Type: GrantFiled: June 13, 2007Date of Patent: June 19, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Ulrich Reiser, Peter Ettmayer, Oliver Kraemer, Peter Sennhenn, Walter Spevak
-
Publication number: 20090258857Abstract: The present invention encompasses compounds of general formula (1) wherein R1, M1, L1 and Q are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.Type: ApplicationFiled: June 13, 2007Publication date: October 15, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Ulrich Reiser, Peter Ettmayer, Oliver Kraemer, Peter Sennhenn, Walter Spevak
-
Publication number: 20090186901Abstract: The present invention relates to new heterocyclic compounds of general formula (1) wherein the groups R1 to R7, k, X and Y have the meanings given in the claims and specification, the isomers and salts thereof as well as the use thereof as medicaments. Background to the invention WO 01/36423 describes 3,4-dihydrospiro[chromene-2,4?-piperidine] derivatives for treating diseases of the central nervous system. Spirocyclic heterocycles as ?-opioid receptor ligands for treating pain and anxiety states as well as diseases of the gastrointestinal tract are known from WO 2005/033073. The aim of the present invention is to indicate new active substances which can be used for the prevention and/or treatment of diseases characterised by excessive or abnormal cell proliferation.Type: ApplicationFiled: May 3, 2007Publication date: July 23, 2009Inventors: Ulrich Reiser, Oliver Kraemer, Peter Sennhenn, Walter Spevak
-
Publication number: 20070004684Abstract: The present invention encompasses compounds of general formula (1) wherein R2 to R5 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.Type: ApplicationFiled: June 8, 2006Publication date: January 4, 2007Applicant: Boehringer Ingelheim International GmbHInventors: Peter Sennhenn, Andreas Mantoulidis, Matthias Treu, Ulrike Tontsch-Grunt, Walter Spevak, Darryl McConnell, Andreas Schoop, Ralph Brueckner, Albrecht Jacobi, Ulrich Guertler, Gisela Schnapp, Christian Klein, Frank Himmelsbach, Alexander Pautsch, Bodo Betzmeier, Lars Herfurth, Juergen Mack, Dieter Wiedenmayer, Gerd Bader, Ulrich Reiser
-
Patent number: RE48992Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.Type: GrantFiled: October 31, 2019Date of Patent: March 29, 2022Assignee: Helmholtz Zentrum München-Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn